Ascom, Enterasys partner on 802.11n VoWiFi for healthcare

Jeff Byers | | Health Exec | Precision Medicine
Ascom Wireless Solutions, supplier of onsite mobile mission-critical communications, and Enterasys Networks, provider of wired and wireless network infrastructure and security tools, have certified interoperability between the Ascom i62 Voice-over-WiFi handset and the Enterasys 3600 series wireless access points.

The technologies were jointly tested at the Ascom Interoperability Lab and the Enterasys Wireless Interoperability Lab, according to Andover, Mass.-based Enterasys. The interoperability testing started with an emphasis on basic connectivity, with further testing for high security, mobility and performance during roaming.

Ongoing interoperability testing will be performed for new software releases or feature enhancements to ensure continual interoperability between the companies' tools, Enterasys added.

Jeff Byers

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.